Free Trial
TSE:GUD

Knight Therapeutics (GUD) Stock Price, News & Analysis

C$6.11
-0.03 (-0.49%)
(As of 05/17/2024 04:00 PM ET)
Today's Range
C$6.10
C$6.17
50-Day Range
C$5.23
C$6.15
52-Week Range
C$4.35
C$6.22
Volume
32,321 shs
Average Volume
70,602 shs
Market Capitalization
C$619.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$6.75

Knight Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
10.5% Upside
C$6.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Knight Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
C$1.88 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

GUD stock logo

About Knight Therapeutics Stock (TSE:GUD)

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

GUD Stock Price History

GUD Stock News Headlines

GUD:CA Knight Therapeutics Inc.
Knight Therapeutics (TSE:GUD) PT Raised to C$5.75
Knight Therapeutics Inc (GUD)
Knight Therapeutics Inc (04K.SG)
Stocks in play: Knight Therapeutics Inc.
Stocks in play: Knight Therapeutics Inc.,
Closing Bell: Knight Therapeutics Inc flat on Thursday (GUD)
Knight Therapeutics (KHTRF) Receives a Buy from RBC Capital
Knight Therapeutics Reports Second Quarter 2023 Results
See More Headlines
Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
5/21/2024
Next Earnings (Estimated)
8/08/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
725
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$6.75
High Stock Price Target
C$7.50
Low Stock Price Target
C$5.75
Potential Upside/Downside
+10.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

P/E Growth
-1013.5
Net Income
C$-17,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$332.21 million
Cash Flow
C$1.59 per share
Book Value
C$7.53 per share

Miscellaneous

Free Float
N/A
Market Cap
C$619.43 million
Optionable
Not Optionable
Beta
0.46
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 55)
    L.L.B., M.B.A., Executive Chairman
    Comp: $250.94k
  • Ms. Samira Sakhia BCom (Age 56)
    CA, CPA, MBA, President, CEO & Director
    Comp: $674.28k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Business Officer
  • Mr. Jeff Martens
    Global Vice President of Commercial
  • Mr. Stephani Saverio
    Vice President of Business Development
  • Mr. Leopoldo Bosano
    Vice-President of Manufacturing & Operations
  • Ms. Monica Percario
    Global Vice President of Scientific Affairs
  • Mr. Henrique Dias
    Global Director of Marketing
  • Ms. Susan Caroline Emblem
    Global Vice President of Human Resources

GUD Stock Analysis - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GUD shares.
View GUD analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price target for 2024?

3 brokerages have issued 1 year price objectives for Knight Therapeutics' stock. Their GUD share price targets range from C$5.75 to C$7.50. On average, they expect the company's share price to reach C$6.75 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts price targets for GUD
or view top-rated stocks among Wall Street analysts.

How have GUD shares performed in 2024?

Knight Therapeutics' stock was trading at C$5.19 at the start of the year. Since then, GUD stock has increased by 17.7% and is now trading at C$6.11.
View the best growth stocks for 2024 here
.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our GUD earnings forecast
.

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc. (TSE:GUD) posted its earnings results on Thursday, March, 21st. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.02 by $0.05. The firm earned $74.20 million during the quarter, compared to analyst estimates of $78.37 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 2.21% and a negative net margin of 5.25%.

What other stocks do shareholders of Knight Therapeutics own?
How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:GUD) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners